Turk Ilac ve Serum Sanayi AS

As of September 30, 2025, Turk Ilac ve Serum Sanayi AS carries a market capitalization of 3.67B, placing it among publicly traded companies globally. Its enterprise value stands at 6.40B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2025, Turk Ilac ve Serum Sanayi AS has 1.04B shares outstanding.

These figures are as of September 30, 2025. The price-to-sales ratio is 1.07, and the price-to-book ratio stands at 1.92.

As of September 30, 2025, Turk Ilac ve Serum Sanayi AS trades at an EV/EBITDA multiple of 9.11 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.87 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 9.32 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 6.40B versus a market cap of 3.67B, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2025, Turk Ilac ve Serum Sanayi AS maintains a current ratio of 1.16, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 143.71, indicating elevated leverage, while an interest coverage ratio of 0.55 demonstrates limited ability to service its debt obligations.

Over the twelve months ended September 30, 2025, Turk Ilac ve Serum Sanayi AS posted a negative return on equity (ROE) of -23.56, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -8.91, reflecting losses generated across the asset base. The company generates approximately 6.33M in revenue per employee across its workforce of 541.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.03 indicates how many times Turk Ilac ve Serum Sanayi AS sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended September 30, 2025, Turk Ilac ve Serum Sanayi AS recorded 215.27M in income tax expense. The company reported a pretax loss of -215.09M and -430.36M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Turk Ilac ve Serum Sanayi AS's stock has declined approximately 73.32% over the past 52 weeks. The 50-day moving average sits at 0.98, while the 200-day moving average is 1.96.

Over the twelve months ended September 30, 2025, Turk Ilac ve Serum Sanayi AS generated 3.43B in revenue and converted that into -430.36M in net income, yielding earnings per share of -0.42. EBITDA reached 702.65M, while operating income came in at 662.51M.

As of September 30, 2025, Turk Ilac ve Serum Sanayi AS holds 12.42M in cash and equivalents against 2.75B in total debt, resulting in a net debt position of 2.64B. Total book value stands at 1.91B, with working capital of 502.55M providing operational flexibility.

Turk Ilac ve Serum Sanayi AS produced 553.17M in operating cash flow over the twelve months ended September 30, 2025. After subtracting -293.58M in capital expenditures, free cash flow totaled 259.60M - equivalent to 0.25 per share.

Over the twelve months ended September 30, 2025, Turk Ilac ve Serum Sanayi AS posted a gross margin of 29.01, reflecting its pricing power and cost economics. The operating margin of 19.33 and net profit margin of -12.56 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2025. Free cash flow yield stands at 7.09, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 9.43, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Turk Ilac ve Serum Sanayi AS shareholders.

Turk Ilac ve Serum Sanayi AS's most recent stock split took place on April 27, 2026 with a 917:5877 split ratio.

As of September 30, 2025, Turk Ilac ve Serum Sanayi AS has an Altman Z-Score of 1.60, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.